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Aims. Patients with diabetic nephropathy are reported to have a high prevalence of left ventricular structural and functional
abnormalities.Thisstudywasdesignedtoassessthedeterminantsofleftventricularmassindex(LVMI)andleftventricularejection
fraction(LVEF)indiabeticpatientsatvariousstagesofchronickidneydisease(CKD).Methods.Thiscross-sectionalstudyenrolled
285 diabetic patients with CKD stages 3 to 5 from our outpatient department of internal medicine. Clinical and echocardiographic
parameters were compared and analyzed. Results. We found a signiﬁcant stepwise increase in LVMI (P<0.001), LVH (P<0.001),
and LVEF < 55% (P = 0.013) and a stepwise decrease in LVEF (P = 0.038) corresponding to advance in CKD stages. Conclusions.
Our ﬁndings suggest that increases in LVMI and decreases in LVEF coincide with advances in CKD stages in patients with diabetes.
1.Introduction
Diabetic nephropathy is one of the major complications of
diabetes mellitus (DM) and one of the major reasons for
renal replacement therapy [1]. The leading cause of mor-
bidity and mortality in patients with diabetic nephropathy
is cardiovascular disease [2]. Cardiovascular risk in this
population can partially be attributed to an increase of
traditional risk factors among people with DM but may also
be related to the risk factors for coexisting chronic kidney
disease (CKD), such as proteinuria, ﬂuid retention, anemia,
oxidative stress, and chronic inﬂammatory state [2–4].
There are a number of hemodynamic and metabolic
disturbances that aﬀect the structure and function of heart
in patients with diabetic nephropathy. The major factors
that contribute to further heart failure in diabetic patients
include cardiac microangiopathy, neuropathy of the cardiac
autonomous nervous system, disturbed metabolism, and
fatty degeneration of the myocardium [5]. These patients
are reported to have a high prevalence of decreased left
ventricular systolic function and increased left ventricular
mass index (LVMI) resulting from pressure and volume
overload [6, 7]. Echocardiographic measures of left ventric-
ular function and structure have been reported to predict
adverse cardiovascular outcomes in a variety of populations
[8, 9]. Therefore,it is important to detect and treat abnormal
geometry and dysfunction of heart early. However, little
is known about the relation between the severity of left
ventricular geometry and dysfunction and renal function
impairment in diabetic patients. The aim of this study was
to compare the LVMI and left ventricular ejection fraction
(LVEF) among diabetic patients with various degrees of2 Experimental Diabetes Research
renal insuﬃciency and identify the independent risk factors
associated with increased LVMI and decreased LVEF in this
population.
2.SubjectsandMethods
2.1. Study Patients and Design. The study was conducted in
a regional hospital in southern Taiwan. In total, 285 diabetic
patients with CKD stages 3 to 5 were enrolled consecutively
from our outpatient department of internal medicine from
January 2007 to May 2010. Patients with evidence of kidney
damage lasting for more than 3 months were classiﬁed into
CKD stage 3, 4, or 5 groups based on estimated glomerular
ﬁltration rate (eGFR) level (mL/min/1.73m2) of 30 to 59, 15
to 29, and <15, respectively, as recommended in the National
Kidney Foundation-Kidney Disease Outcomes Quality Ini-
tiative (K/DOQI) guidelines [10]. Patients with signiﬁcant
mitral valve disease and inadequate image visualization were
excluded. The protocol for this study was approved by our
institutional review board, and all enrolled patients gave
written informed consent.
2.2. Evaluation of Cardiac Structure and Function. The
echocardiographic examination was performed using VIVID
7 (General Electric Medical Systems, Horten, Norway),
with the participant respiring quietly in the left decubitus
position. The echocardiographers were blind to patient data.
Two-dimensional and two-dimensional guided M-mode
images were recorded from the standardized view points.
The echocardiographic measurements included aortic root
diameter, left atrial diameter (LAD), left ventricular internal
diameter in diastole (LVIDd), and left ventricular internal
diameter in systole (LVIDs), LVEF, peak early transmitral
ﬁlling wave velocity (E), and peak late transmitral ﬁlling
wave velocity (A). Left ventricular mass was calculated using
the Devereux-modiﬁed method [11]. LVMI was calculated
by dividing left ventricular mass by body surface area. Left
ventricular hypertrophy (LVH) was deﬁned when LVMI
exceeded 134g/m2 and 110g/m2 for men and women,
respectively [12]. Systolic function was assessed by measur-
ing ejection fraction of left ventricle. Systolic dysfunction
was deﬁned as LVEF <55%. Diastolic function was estimated
by measuring the E/A ratio; a value of <1.0 was considered
diastolic dysfunction.
2.3.CollectionofDemographic,Medical,andLaboratoryData.
Demographic and medical data, including age, gender,
smoking history (ever versus never), and comorbid condi-
tions, were garnered from medical records or interviews with
patients. Study subjects were deﬁned as having DM if their
fasting blood glucose levels were greater than 126mg/dL
or they were taking hypoglycemic agents to control blood
glucose levels. Similarly, participants were deﬁned as hav-
ing hypertension if their systolic blood pressures were
≥140mmHg or diastolic blood pressure ≥90mmHg or they
were taking antihypertensive drugs. Coronary artery disease
was deﬁned if they had a history of typical angina with
positive stress test, angiographically documented coronary
artery disease, and old myocardial infarction or they had
undergone coronary artery bypass surgery or angioplasty.
Cerebrovascular disease was deﬁned if they had a history
of cerebrovascular incidents such as cerebral bleeding and
infarction. Congestive heart failure was deﬁned based on
the Framingham criteria. Body mass index was calculated as
the ratio of weight in kilograms divided by square of height
in meters. Blood and urine samples were obtained within
1 month of enrollment. Laboratory data were measured
from fasting blood samples using an autoanalyzer (Roche
Diagnostics GmbH, D-68298 Mannheim COBAS Integra
400). Serum creatinine was measured by the compensated
Jaﬀ´ e(kineticalkalinepicrate)methodinaRoche/Integra400
Analyzer (Roche Diagnostics, Mannheim, Germany) using
a calibrator traceable to isotope-dilution mass spectrometry
[13]. The value of eGFR was calculated using the 4-variable
equation in the Modiﬁcation of Diet in Renal Disease
(MDRD) study [14]. The HbA1c was measured by Prismus
CLC 385 automated analyzer. Proteinuria was examined
by dipsticks (Hema-Combistix, Bayer Diagnostics). A test
result of 1+ or more was deﬁned as positive. In addi-
tion, information regarding patient medications including
aspirin, angiotensin converting enzyme inhibitors (ACEIs),
angiotensin II receptor blockers (ARBs), non-ACEI/ARB
antihypertensive drugs, and HMG-CoA reductase inhibitors
(statins) during the study period was obtained from medical
records.
2.4. Statistical Analysis. Data are expressed as percentages
or mean ± standard deviation or median (25th–75th
percentile) for triglyceride. Multiple comparisons among
the study groups were performed by one-way analysis of
variance (ANOVA) followed by post hoc test adjusted with
a LSD correction. The relationship between two continuous
variables was assessed by a bivariate correlation method
(Pearson’s correlation). Linear regression analysis was used
to identify the factors associated with LVMI and LVEF.
Signiﬁcant variables in univariate analysis were selected for
multivariate analysis. P value less than 0.05 was considered
signiﬁcant. All statistical operations were performed using
SPSS 12.0 for Windows (SPSS Inc. Chicago, USA).
3. Results
A sc a nb es e e ni nTable 1, a summary of clinical character-
istics organized by CKD stage, we studied 285 nondialyzed
CKD patients (174 men and 111 women, mean age 66.4 ±
11.6 years). The prevalence of LVH and LVEF < 55% was
62.5% and 10.5%, respectively. Stepwise increases in the
prevalence of a history of hypertension, cerebrovascular
disease,andcongestiveheartfailure,pulsepressure,uricacid,
phosphorous, calcium-phosphorous product, proteinuria,
and percentage of non-ACEI/ARB antihypertensive drug
use and stepwise decreases in the diastolic blood pressure,
albumin, hemoglobin, eGFR, and calcium corresponded to
advancement in CKD from stage 3 to 5. In addition, there
was a signiﬁcant trend for a stepwise increase in the LAD,
LVIDd, LVIDs, LVMI, and the prevalence of LVH and LVEF
< 55% and a stepwise decrease in the LVEF corresponding
to advancement in CKD from stage 3 to 5. Figure 1 showsExperimental Diabetes Research 3
Table 1: Clinical characteristics of patients among diﬀerent stages of CKD.
Characteristics Stage 3
(n = 99)
Stage 4
(n = 99)
Stage 5
(n = 87) P for trend All patients
(n = 285)
Age (year) 66.3 ± 12.4 68.4 ± 10.7 64.1 ± 11.5† 0.039 66.4 ± 11.6
Male gender (%) 75.8 58.6∗ 47.1∗ <0.001 61.1
Smoking history (%) 32.3 36.4 28.7 0.540 32.6
Hypertension (%) 79.8 81.8 97.7∗† 0.001 86.0
Coronary artery disease (%) 13.1 13.1 18.4 0.514 14.7
Cerebrovascular disease (%) 10.1 21.2∗ 27.6∗ 0.009 19.3
Congestive heart failure (%) 10.1 15.2 28.7∗† 0.003 17.5
Systolic blood pressure (mmHg) 144.5 ± 21.2 141.2 ± 20.0 148.3 ± 23.7† 0.089 144.6 ± 21.8
Diastolic blood pressure (mmHg) 82.4 ± 12.3 77.4 ± 11.9∗ 76.7 ± 14.1∗ 0.005 78.9 ± 13.0
P u l s ep r e s s u r e( m m H g ) 6 2 . 1± 16.7 63.8 ± 11.7 71.7 ± 19.9∗† 0.001 65.7 ± 18.2
Body mass index (kg/m2) 26.2 ± 4.0 26.3 ± 3.5 25.0 ± 3.8∗† 0.043 25.9 ± 3.8
Laboratory parameters
Albumin (g/L) 41.3 ± 3.5 39.9 ± 3.9∗ 37.3 ± 4.5∗† <0.001 39.6 ± 4.3
Fasting glucose (mmol/L) 8.2 ± 3.2 8.0 ± 3.8 8.3 ± 4.7 0.896 8.1 ± 3.9
HbA1c (%) 7.5 ±1.48 .1 ±2.1∗ 7.4 ±1.8† 0.032 7.7 ±1.8
Triglyceride (mmol/L) 1.8 (1.1–2.4) 1.8 (1.4–2.6) 1.8 (1.2–2.7) 0.173 1.8 (1.2–2.6)
Total cholesterol (mmol/L) 5.0 ± 1.1 5.1 ± 1.3 5.2 ± 1.4 0.544 5.1 ± 1.3
Hemoglobin (g/L) 128.8 ± 18.7 115.4 ± 19.2∗ 93.1 ± 13.4∗† <0.001 113.2 ± 22.7
Baseline eGFR (mL/min/1.73 m2) 40.5 ± 6.6 23.1 ± 4.5∗ 10.3 ± 3.0∗† <0.001 25.2 ± 13.3
Calcium (mmol/L) 2.4 ± 0.2 2.4 ± 0.2 2.3 ± 0.2∗† <0.001 2.4 ± 0.2
Phosphate (mmol/L) 1.1 ± 0.2 1.3 ± 0.2∗ 1.6 ± 0.4∗† <0.001 1.3 ± 0.3
Calcium-phosphorous product (mmol2/L2)2 . 8 ± 0.5 3.1 ± 0.6∗ 3.6 ± 0.8∗† <0.001 3.1 ± 0.7
Uric acid (μmol/L) 456.7 ± 113.3 505.4 ± 138.6∗ 530.8 ± 143.3∗ 0.001 496.5 ± 135.1
Proteinuria (%) 47.5 75.5∗ 98.9∗† <0.001 72.9
Medications
Aspirin use (%) 30.2 32.3 34.5 0.826 32.2
ACEI and/or ARB use (%) 80.2 83.3 63.1∗† 0.003 76.1
Non-ACEI/ARB antihypertensive drug use (%) 67.7 80.8∗ 94.3∗† <0.001 80.4
Statin use (%) 36.5 29.2 31.0 0.532 32.2
Echocardiographic data
Aortic root diameter (cm) 3.3 ± 0.4 3.3 ± 0.4 3.2 ± 0.4 0.262 3.3 ± 0.4
LAD (cm) 3.7 ± 0.6 3.9 ± 0.6 4.1 ± 0.6∗† < 0.001 3.9 ± 0.6
LVIDd (cm) 4.8 ± 0.7 4.9 ± 0.8 5.1 ± 0.7∗† 0.005 4.9 ± 0.8
LVIDs (cm) 2.9 ± 0.7 3.1 ± 0.8 3.3 ± 0.8∗† 0.002 3.1 ± 0.8
LVMI (g/m2) 129.5 ± 43.5 139.1 ± 52.4 167.1 ± 45.9∗† <0.001 144.3 ± 49.8
LVH (%) 44.4 61.6∗ 83.9∗† <0.001 62.5
LVEF (%) 69.0 ± 11.1 67.0 ± 11.7 64.5 ± 13.2∗ 0.038 66.9 ± 12.1
LVEF < 55% (%) 4.0 11.1∗ 17.2∗ 0.013 10.5
E/A < 1 (%) 78.9 84.9 75.0 0.250 79.8
CKD: chronic kidney disease; eGFR: estimated glomerular ﬁltration rate; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor
blocker; LAD: left atrial diameter; LVIDd: left ventricular internal diameter in diastole; LVIDs: left ventricular internal diameter in systole; LVMI: left
ventricular mass index; LVH: left ventricular hypertrophy; LVEF: left ventricular ejection fraction; E: peak early transmitral ﬁlling wave velocity; A: peak late
transmitral ﬁlling wave velocity.
∗P<0.05 compared to stage 3; †P<0.05 compared to stage 4.
the signiﬁcant trend for a stepwise increase in LVMI (a) and
theprevalenceofLVH(b)correspondingtotheadvancement
inCKDfromstage3to5.Figure 2showsthesigniﬁcanttrend
for a stepwise decrease in LVEF (a) and a stepwise increase
in the prevalence of LVEF < 55% (b) corresponding to the
advancement in CKD from stage 3 to 5.
As seen in Table 2 which summarizes our ﬁndings on
the possible determinants of LVMI in our study patients,
univariate analysis showed a signiﬁcant positive correla-
tion between LVMI and being male, a history of smok-
ing, coronary artery disease, and congestive heart failure,
advancedCKDstages,systolicbloodpressure,pulsepressure,4 Experimental Diabetes Research
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Figure 1: There was a signiﬁcant trend for a stepwise increase in
left ventricular mass index (LVMI) (P < 0.001 for trend) (a) and the
prevalence of left ventricular hypertrophy (LVH) (44.4%, 61.6%,
and 83.9%, resp.; P < 0.001 for trend) (b) corresponding to the
advancement in chronic kidney disease from stage 3 to 5.
phosphorous, proteinuria, aspirin use, and non-ACEI/ARB
antihypertensive drug use and negative correlation between
LVMI and albumin, hemoglobin, calcium, and ACEI and/or
ARB use. Further forward multivariate analysis revealed a
signiﬁcant correlation between increases in LVMI and being
male, a history of congestive heart failure, advanced CKD
stages, high systolic blood pressure, and low serum albumin
level.
Table 3 summarizes the results of our analysis of possible
determinants of LVEF in our study patients. Univariate
analysis showed a positive correlation between LVEF and
albumin, calcium, and ACEI and/or ARB use and a negative
correlation with being male, a history of coronary artery
disease and congestive heart failure, advanced CKD stages,
uric acid, phosphorous, aspirin use, and non-ACEI/ARB
antihypertensive drug use. Further forward multivariate
analysis revealed a correlation between decreased LVEF and
being male, a history of coronary artery disease, advanced
CKD stages, low serum albumin level, and ACEI and/or ARB
use.
P = 0.038 for trend
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Figure 2:Therewasasigniﬁcanttrendforastepwisedecreaseinleft
ventricular ejection fraction (LVEF) (P = 0.038 for trend) (a) and
stepwise increase in the prevalence of LVEF < 55% (4.0%, 11.1%,
and 17.2%, resp.; P < 0.013 for trend) (b) corresponding to the
advancement in chronic kidney disease from stage 3 to 5.
4. Discussion
In the present study, we evaluated the determinants of LVMI
and LVEF in diabetic patients with various stages of CKD.
We found a signiﬁcant trend for a stepwise increase in LVMI
and the prevalence of LVH and LVEF < 55% and a stepwise
decrease in LVEF corresponding to advancement in CKD
stage.
Patients with diabetic nephropathy have a high preva-
lence of LVH and left ventricular systolic dysfunction,
two disorders that contribute majorly to increased risk of
cardiovascular death [2–4]. Structural and functional abnor-
malities of the heart are common in patients with diabetic
nephropathy because of pressure and volume overload [15,
16]. The prevalence of LVH ranges from 17% to 42% in
patients with hypertension, 22% to 47% in patients with
CKD, and 68.5% of dialysis patients, and LVH occurs in only
3.2% of the general population [8, 17, 18]. However, the
prevalence of LVH in our study patients was relatively high
(62.5%), which might be explained by the fact that all of
the patients included in our study had diabetic nephropathy.Experimental Diabetes Research 5
Table 2: Determinants of left ventricular mass index (LVMI) in study patients.
Characteristics Univariate Multivariate (forward)
Standardized coeﬃcient β P Standardized coeﬃcient β P
Age (year) 0.012 0.842 — —
Male versus female 0.117 0.048 0.211 <0.001
Smoking(ever versus never) 0.126 0.033 — —
Coronary artery disease 0.147 0.013 — —
Cerebrovascular disease 0.024 0.681 — —
Congestive heart failure 0.262 <0.001 0.196 0.001
CKD stage 0.301 <0.001 0.262 <0.001
Systolic blood pressure (mmHg) 0.225 <0.001 0.203 <0.001
Diastolic blood pressure (mmHg) 0.095 0.118 — —
Pulse pressure (mmHg) 0.202 0.001 — —
Body mass index (kg/m2) 0.049 0.413 — —
Laboratory parameters
Albumin (g/L) −0.321 <0.001 −0.132 0.032
Fasting glucose (mmol/L) 0.027 0.653 — —
HbA1c (%) −0.052 0.389 — —
Triglyceride (Log mmol/L) −0.034 0.570 — —
Cholesterol (mmol/L) 0.047 0.436 — —
Hemoglobin (g/L) −0.212 <0.001 — —
Calcium (mmol/L) −0.185 0.002 — —
Phosphate (mmol/L) 0.182 0.002 — —
Calcium-phosphorous product (mmol2/L2) 0.114 0.060 — —
Uric acid (μmol/L) 0.117 0.052 — —
Proteinuria 0.216 <0.001 — —
Medications ——
Aspirin use (%) 0.190 0.001 — —
ACEI and/or ARB use (%) −0.167 0.005 — —
Non-ACEI and/or ARB antihypertensive drug use (%) 0.188 0.001 — —
Statin use (%) −0.041 0.502 — —
Values expressed as standardized coeﬃcient β. Abbreviations are the same as Table 1.
The prevalence of left ventricular systolic dysfunction in
patients with chronic renal insuﬃciency is approximately
7.6%–22% [8, 19]. In our patients, the prevalence of LVEF <
55% was 10.5%, which is compatible with previous ﬁndings.
DM, hypertension, and dyslipidemia are traditional car-
diovascular risk factors. In addition to these traditional risk
factors, patients with CKD may have other risk factors for
increase cardiovascular risk such as inﬂammation, oxidative
stress, anemia, metabolic disorders, calcium-phosphorous
disorders, hypervolemia, and structural and functional
abnormalities of heart, which may help to explain the high
cardiovascularmorbidityandmortalityinsuchpatients[20–
25]. LVH, a common ﬁnding in patients with CKD, has been
reported to advance with decreases in glomerular ﬁltration
rate [3]. Hillege et al. found that there was also a signiﬁcant
correlation between the deterioration of congestive heart
failure and the progression of renal failure [26]. Our study
found that, with the decrease of renal function, there was
a signiﬁcant trend for a stepwise increase in LVMI and the
prevalence of LVH and LVEF < 55% and a stepwise decrease
in LVEF in patients with diabetic nephropathy, which is
consistent with the previous ﬁndings.
Low serum albumin level has been regarded as indicator
of malnutrition. Malnutrition may worsen the outcome
of CKD by aggravating existing inﬂammation and heart
failure [27]. Hypoalbuminemia has been correlated with
left ventricular structure and function [25, 28, 29]. Kursat
et al. [25], evaluating the relationship between the degree
of malnutrition and echocardiographic parameters in 72
hemodialysis patients, found that the malnutrition index,
calculatedusingSubjectiveGlobalAssessment,hadapositive
correlation with left ventricular mass and index. They cited
inadequate volume control as an explanation for their
ﬁndings. Volume overload may substantially decrease energy
and protein intake, suggesting a possible relation between
volume overload and malnutrition. In addition, volume
overload may increase the diastolic wall stress and in turn
cause the development of LVH [25]. Trovato et al. [29],6 Experimental Diabetes Research
Table 3: Determinants of left ventricular ejection fraction (LVEF) in study patients.
Characteristics Univariate Multivariate (forward)
Standardized coeﬃcient β P Standardized coeﬃcient β P
Age (year) 0.062 0.297 — —
Male versus female −0.223 <0.001 −0.227 <0.001
Smoking(ever versus never) −0.090 0.130 — —
Coronary artery disease −0.169 0.004 −0.153 0.008
Cerebrovascular disease −0.071 0.235 — —
Congestive heart failure −0.155 0.009 — —
CKD stage −0.151 0.011 −0.173 0.007
Systolic blood pressure (mmHg) −0.038 0.528 — —
Diastolic blood pressure (mmHg) −0.092 0.130 — —
Pulse pressure (mmHg) 0.020 0.747 — —
Body mass index (kg/m2) 0.010 0.871 — —
Laboratory parameters
Albumin (g/L) 0.258 < 0.001 0.188 0.003
Fasting glucose (mmol/L) −0.097 0.107 — —
HbA1c (%) −0.040 0.509
Triglyceride (Log mmol/L) −0.039 0.518 — —
Cholesterol (mmol/L) −0.069 0.247 — —
Hemoglobin (g/L) 0.103 0.083 — —
Calcium (mmol/L) 0.122 0.044
Phosphate (mmol/L) −0.168 0.005
Calcium-phosphorous product (mmol2/L2) −0.103 0.088 — —
Uric acid (μmol/L) −0.146 0.015 — —
Proteinuria −0.096 0.106 — —
Medications
Aspirin use (%) −0.132 0.028 — —
ACEI and/or ARB use (%) 0.203 0.001 0.143 0.014
Non-ACEI and/or ARB antihypertensive drug use (%) 0.048 0.422 — —
Statin use (%) 0.004 0.951 — —
Values expressed as standardized coeﬃcient β. Abbreviations are the same as Table 1.
also investigating the correlation between heart failure
and nutritional status in hemodialysis patients, reported
an association between low serum albumin level and
decreased LVEF. Our results consistently demonstrate inde-
pendent association between low serum albumin levels and
increasedLVMIanddecreasedLVEFinpatientswithdiabetic
nephropathy.
One limitation of this study was that it had a cross-
sectional design, and thus the predictors of cardiovascular
eventscouldnotbeevaluated.Furtherprospectivestudiesare
needed to conﬁrm our ﬁndings.
In conclusion, our results found a signiﬁcant trend for
a stepwise increase in LVMI and the prevalence of LVH and
LVEF < 55% and a stepwise decrease in LVEF corresponding
to advancement in CKD stage in diabetic patients.
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